{"id":"antipseudomonal-beta-lactam-antibiotic","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Phlebitis at injection site"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL3780336","moleculeType":"Small molecule","molecularWeight":"188.18"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Antipseudomonal beta-lactams are beta-lactam antibiotics engineered to penetrate and remain stable against the outer membrane of Pseudomonas aeruginosa while inhibiting cross-linking of peptidoglycan in the bacterial cell wall. This class includes agents such as piperacillin, ceftazidime, and carbapenems, which are designed to overcome the intrinsic resistance mechanisms of Pseudomonas. The resulting cell wall instability causes bacterial lysis and death.","oneSentence":"Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell wall rupture and bacterial death, with activity against Pseudomonas aeruginosa and other gram-negative organisms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:56.402Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pseudomonas aeruginosa infections (respiratory, urinary, wound, bloodstream)"},{"name":"Nosocomial/hospital-acquired infections caused by gram-negative organisms"}]},"trialDetails":[{"nctId":"NCT04983901","phase":"PHASE2","title":"PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-14","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm","enrollment":100},{"nctId":"NCT02449031","phase":"","title":"Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-05-05","conditions":"Pseudomonas Aeruginosa in Cystic Fibrosis","enrollment":409},{"nctId":"NCT02795949","phase":"PHASE3","title":"Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2016-10","conditions":"Enterobacteriaceae Infections","enrollment":344},{"nctId":"NCT02070757","phase":"PHASE3","title":"Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2014-09-02","conditions":"Healthcare-Associated Pneumonia, Ventilator-Associated Pneumonia, Lung Diseases","enrollment":726},{"nctId":"NCT03622450","phase":"PHASE2, PHASE3","title":"The Effect of Colistin Inhalation on Ventilator Associated Pneumonia","status":"COMPLETED","sponsor":"Nourhan Hassan Osama Thuraya Mohamed","startDate":"2016-01-02","conditions":"Ventilator Associated Pneumonia","enrollment":40},{"nctId":"NCT01667094","phase":"PHASE4","title":"A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis","status":"UNKNOWN","sponsor":"The Alfred","startDate":"2012-09","conditions":"Cystic Fibrosis","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ampicillin","Trimethoprim/sulfamethoxazole","Cefuroxime","Amoxicillin/clavulanate","Ciprofloxacin"],"phase":"phase_3","status":"active","brandName":"Antipseudomonal beta-lactam antibiotic","genericName":"Antipseudomonal beta-lactam antibiotic","companyName":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","companyId":"fundaci-n-p-blica-andaluza-para-la-gesti-n-de-la-investigaci-n-en-sevilla","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell wall rupture and bacterial death, with activity against Pseudomonas aeruginosa and other gram-negative organisms. Used for Pseudomonas aeruginosa infections (respiratory, urinary, wound, bloodstream), Nosocomial/hospital-acquired infections caused by gram-negative organisms.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}